What happened
Researchers at the University of Essex used artificial intelligence to redesign antibodies into intrabodies that can act directly inside human cells.
This approach is aimed at developing new treatments for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
Why it matters
Intracellular proteins are common culprits in neurodegenerative diseases, but standard antibodies cannot cross cell membranes to reach them.
By using AI to engineer intrabodies, scientists may overcome this barrier and open a new class of therapies for conditions that currently have limited treatment options.
Key facts
The work was conducted at the University of Essex.
AI was used to redesign antibodies for intracellular action.
The targeted diseases include Alzheimer's, Parkinson's, and ALS.
What to watch next
Whether these AI-designed intrabodies demonstrate efficacy and safety in future preclinical and clinical studies.
If successful, the approach could be adapted to other diseases driven by intracellular proteins.